4.2 Article

Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease Brain

期刊

PARKINSONS DISEASE
卷 2012, 期 -, 页码 -

出版社

HINDAWI LTD
DOI: 10.1155/2012/614212

关键词

-

资金

  1. PHS Grant [R01 NS36711-09, R24 MH 068855]
  2. NIH Grant [T32 GM074905]
  3. Robert P. and Judith N. Goldberg Foundation
  4. Bumpus Foundation
  5. National Institute of Neurological Disorders and Stroke [U24 NS072026]
  6. National Institute on Aging [P30 AG19610]
  7. Arizona Department of Health Services (Arizona Alzheimer's Research Center) [211002]
  8. Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]
  9. Michael J. Fox Foundation for Parkinson's Research
  10. Harvard Brain Tissue Resource Center
  11. Human Brain and Spinal Fluid Resource Center at VA West Los Angeles Healthcare Center
  12. NINDS/NIMH
  13. National Multiple Sclerosis Society
  14. Department of Veterans

向作者/读者索取更多资源

Duplications and triplications of the alpha-synuclein (SNCA) gene increase risk for PD, suggesting increased expression levels of the gene to be associated with increased PD risk. However, past SNCA expression studies in brain tissue report inconsistent results. We examined expression of the full-length SNCA transcript (140 amino acid protein isoform), as well as total SNCA mRNA levels in 165 frontal cortex samples (101 PD, 64 control) using quantitative real-time polymerase chain reaction. Additionally, we evaluated the relationship of eight SNPs in both 5' and 3' regions of SNCA with the gene expression levels. The association between postmortem interval (PMI) and SNCA expression was different for PD and control samples: SNCA expression decreased with increasing PMI in cases, while staying relatively constant in controls. For short PMI, SNCA expression was increased in PD relative to control samples, whereas for long PMI, SNCA expression in PD was decreased relative to control samples.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Genetics & Heredity

RAREsim: A simulation method for very rare genetic variants

Megan Null, Josee Dupuis, Pezhman Sheinidashtegol, Ryan M. Layer, Christopher R. Gignoux, Audrey E. Hendricks

Summary: Identification of rare-variant associations is crucial for understanding the genetic architecture of complex traits and diseases. Existing simulation methods have limitations in using real-variant annotation and accurately estimating the number of rare variants. This study presents a flexible and accurate rare-variant simulation algorithm, RAREsim, that can simulate the expected variant distribution and provide real-variant annotations.

AMERICAN JOURNAL OF HUMAN GENETICS (2022)

Article Immunology

Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019

Yijia Li, Linda J. Harrison, Kara W. Chew, Judy S. Currier, David A. Wohl, Eric S. Daar, Teresa H. Evering, Ryan Wu, Mark Giganti, Justin Ritz, Arzhang Cyrus Javan, Robert W. Coombs, Carlee Moser, Michael D. Hughes, Joseph J. Eron, Davey M. Smith, Jonathan Z. Li

Summary: This exploratory analysis of placebo recipients in the ACTIV2/A5401 platform trial showed that high anterior nasal RNA levels and detectable plasma RNA were associated with delayed symptom improvement in acute Coronavirus Disease 2019.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19

Babafemi O. Taiwo, Kara W. Chew, Carlee Moser, David Alain Wohl, Eric S. Daar, Jonathan Z. Li, Alexander L. Greninger, Christoph Bausch, Thomas Luke, Keila Hoover, Gene Neytman, Mark J. Giganti, Maxine Olefsky, Arzhang Cyrus Javan, Courtney Fletcher, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith

Summary: SAB-185, a novel IgG polyclonal immunoglobulin product, showed antiviral activity and safety in nonhospitalized adults with mild-moderate COVID-19.

JOURNAL OF INFECTIOUS DISEASES (2023)

Correction Multidisciplinary Sciences

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 (vol 13, 4931, 2022)

Kara W. Chew, Carlee S. Moser, Eric S. A. Daar, David A. Z. Wohl, Jonathan Z. W. Li, Robert W. Coombs, Justin Ritz, Mark Giganti, Arzhang Cyrus Javan, Yijia C. Li, Manish C. Choudhary, Rinki Deo, Carlos Malvestutto, Paul Klekotka, Karen Price, Ajay Nirula, William Fischer, Veenu M. Bala, Ruy M. S. Ribeiro, Alan S. V. Perelson, Courtney V. J. Fletcher, Joseph J. S. Eron, Judith S. D. Currier, Michael D. M. Hughes, Davey M. Smith

NATURE COMMUNICATIONS (2023)

Article Medicine, General & Internal

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

Teresa H. Evering, Kara W. Chew, Mark J. Giganti, Carlee Moser, Mauricio Pinilla, David Alain Wohl, Judith J. Currier, Joseph Eron, Arzhang Cyrus Javan, Rachel Bender Ignacio, David Margolis, Qing Zhu, Ji Ma, Lijie Zhong, Li Yan, Ulises D'Andrea Nores, Keila Hoover, Bharat Mocherla, Manish C. Choudhary, Rinki Deo, Justin Ritz, William A. Fischer, Courtney Fletcher, Jonathan Z. Li, Michael D. Hughes, Davey Smith, Eric S. Daar

Summary: This randomized controlled trial assessed the safety and efficacy of amubarvimab plus romlusevimab. The combination treatment significantly reduced the risk of hospitalization and/or death among nonhospitalized adults with mild to moderate SARSCoV-2 infection at high risk for progression to severe disease.

ANNALS OF INTERNAL MEDICINE (2023)

Article Medicine, General & Internal

Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection

Rinki Deo, Manish C. Choudhary, Carlee Moser, Justin Ritz, Eric S. Daar, David A. Wohl, Alexander L. Greninger, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith, Kara W. Chew, Jonathan Z. Li

Summary: The study retrospectively analyzed untreated outpatients with mild to moderate COVID-19 and found that symptom and viral rebound were common, but the combination of symptom and viral rebound was rare.

ANNALS OF INTERNAL MEDICINE (2023)

Article Immunology

Effect of Immune-Modulatory Interventions on Asymptomatic Cytomegalovirus Shedding During Suppressive Antiretroviral Therapy

Elizabeth Hastie, Carlee Moser, Xin Sun, Jeffrey Lennox, Priscilla Y. Hsue, Ronald J. Bosch, Steven Deeks, Milenka Meneses, Michael M. Lederman, Peter Hunt, Timothy J. Henrich, Vincent C. Marconi, Sara Gianella

Summary: The immune-modulators ruxolitinib and sirolimus did not have a significant effect on CMV DNA shedding in people with HIV on suppressive antiretroviral therapy. However, higher CMV DNA levels were associated with immune markers related to HIV persistence and mortality rates. CMV is a known contributor to the persistent inflammation and immune dysfunction observed in HIV.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Clinical Neurology

Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function A Meta-analysis of Community-Based Cohorts

Yuankai Zhang, Xue Liu, Kerri L. Wiggins, Nuzulul L. Kurniansyah, Xiuqing Guo, Amanda L. Rodrigue, Wei Zhao, Lisa R. Yanek, Scott M. Ratliff, Achilleas Pitsillides, Juan Sebastian Aguirre Patino, Tamar Sofer, Dan E. Arking, Thomas R. Austin, Alexa S. Beiser, John Blangero, Eric E. Boerwinkle, Jan Bressler, Joanne E. Curran, Lifang Hou, Timothy J. Hughes, Sharon L. R. Kardia, Lenore J. Launer, Daniel Levy, Thomas H. Mosley, Ilya M. Nasrallah, Stephen S. Rich, Jerome Rotter, Sudha Seshadri, Wassim Tarraf, Kevin A. Gonzalez, Vasan Ramachandran, Kristine Yaffe, Paul A. Nyquist, Bruce M. Psaty, Charles C. DeCarli, Jennifer M. Smith, David C. Glahn, Hector M. Gonzalez, Joshua R. Bis, Myriam L. Fornage, Susan Heckbert, Annette L. Fitzpatrick, Chunyu Liu, Claudia L. Satizabal

Summary: This study found that higher mitochondrial DNA copy number (CN) in blood is associated with better cognitive function in both current and future settings, but is not causally related to cognition. This suggests that circulating mtDNA CN could serve as a biomarker of cognitive function in the community.

NEUROLOGY (2023)

Correction Multidisciplinary Sciences

Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (vol 12, 3417, 2021)

Itziar de Rojas, Sonia Moreno-Grau, Niccolo Tesi, Benjamin Grenier-Boley, Victor Andrade, Iris Jansen, Nancy L. Pedersen, Najada Stringa, Anna Zettergren, Isabel Hernandez, Laura Montrreal, Carmen Antunez, Anna Antonell, Rick M. Tankard, Joshua Bis, Rebecca Sims, Celine Bellenguez, Ines Quintela, Antonio Gonzalez-Perez, Miguel Calero, Emilio Franco-Macias, Juan Macias, Rafael Blesa, Laura Cervera-Carles, Manuel Menendez-Gonzalez, Ana C. Frank-Garcia, Jose Luis W. Royo, Fermin Moreno, Raquel Huerto Vilas, Miquel Baquero, Monica Diez-Fairen, Carmen Lage, Sebastian Garcia-Madrona, Pablo Garcia-Gonzalez, Emilio Alarcon-Martin, Sergi Valero, Oscar Sotolongo-Grau, Abbe Ullgren, Adam C. Naj, Afina W. Lemstra, Alba Benaque, Alba Perez-Cordon, Alberto L. Benussi, Alberto Rabano, Alessandro Padovani, Alessio Squassina, Alexandre de Mendonca, Alfonso M. Arias Pastor, Almar A. L. Kok, Alun Meggy, Ana Belen Pastor, Ana Espinosa, Anais Corma-Gomez, Angel Martin Montes, Angela Sanabria, Anita W. DeStefano, Anja Schneider, Annakaisa Haapasalo, Anne Kinhult Stahlbom, Anne Tybjaerg-Hansen, Annette M. Hartmann, Annika Spottke, Arturo Corbaton-Anchuelo, Arvid B. Rongve, Barbara Borroni, Beatrice Arosio, Benedetta Nacmias, Borge G. Nordestgaard, Brian W. Kunkle, Camille Charbonnier, Carla Abdelnour, Carlo Masullo, Carmen Martinez Rodriguez, Carmen Munoz-Fernandez, Carole Dufouil, Caroline Graff, Catarina Ferreira, Caterina Chillotti, Chandra A. Reynolds, Chiara Fenoglio, Christine Van Broeckhoven, Christopher Clark, Claudia Pisanu, Claudia L. Satizabal, Clive Holmes, Dolores Buiza-Rueda, Dag Aarsland, Dan Rujescu, Daniel Alcolea, Daniela Galimberti, David Wallon, Davide Seripa, Edna Grunblatt, Efthimios Dardiotis, Emrah Duezel, Elio Scarpini, Elisa Conti, Elisa Rubino, Ellen Gelpi, Eloy Rodriguez-Rodriguez, Emmanuelle Duron, Eric Boerwinkle, Evelyn Ferri, Fabrizio Tagliavini, Fahri Kuecuekali, Florence Pasquier, Florentino Sanchez-Garcia, Francesca Mangialasche, Frank Jessen, Gael Nicolas, Geir Selbaek, Gemma K. Ortega, Genevieve Chene, Georgios Hadjigeorgiou, Giacomina Rossi, Gianfranco Spalletta, Giorgio Giaccone, Giulia Grande, Giuliano Binetti, Goran Papenberg, Harald Hampel, Henri Bailly, Henrik Zetterberg, Hilkka Soininen, Ida Karlsson, Ignacio Alvarez, Ildebrando Appollonio, Ina Giegling, Ingmar Skoog, Ingvild Saltvedt, Innocenzo Rainero, Irene Rosas Allende, Jakub Hort, Janine Diehl-Schmid, Jasper Van Dongen, Jean-Sebastien Vidal, Jenni Lehtisalo, Jens Wiltfang, Jesper Qvist Thomassen, Johannes Kornhuber, Jonathan A. Haines, Jonathan Vogelgsang, Juan Pineda, Juan Fortea, Julius Popp, Juergen Deckert, Katharina Buerger, Kevin Morgan, Klaus Fliessbach, Kristel Sleegers, Laura Molina-Porcel, Lena Kilander, Leonie Weinhold, Lindsay Farrer, Li-San Wang, Luca Kleineidam, Lucia A. Farotti, Lucilla Parnetti, Lucio Tremolizzo, Lucrezia Hausner, Luisa Benussi, Lutz Froelich, M. Arfan Ikram, M. Candida Deniz-Naranjo, Magda Tsolaki, Maitee Rosende-Roca, Malin Lowenmark, Marc Hulsman, Marco Spallazzi, Margaret H. Pericak-Vance, Margaret Esiri, Maria Bernal Sanchez-Arjona, Maria Carolina Dalmasso, Maria Teresa T. Martinez-Larrad, Marina Arcaro, Markus Noethen, Marta Fernandez-Fuertes, Martin Dichgans, Martin Ingelsson, Martin Herrmann, Martin Scherer, Martin Vyhnalek, Mary M. Kosmidis, Mary M. Yannakoulia, Matthias Schmid, Michael J. Ewers, Michael T. Heneka, Michael Wagner, Michela Scamosci, Miia Kivipelto, Mikko Hiltunen, Miren Zulaica, Montserrat Alegret, Myriam Fornage, Natalia Roberto, Natasja van Schoor, Nazib Seidu, Nerisa Banaj, Nicola Armstrong, Nikolaos Scarmeas, Norbert A. Scherbaum, Oliver Goldhardt, Oliver Hanon, Oliver Peters, Olivia Anna Skrobot, Olivier Quenez, Ondrej Lerch, Paola Bossu, Paolo Caffarra, Paolo Dionigi Rossi, Paraskevi Sakka, Patrizia Mecocci, Per Hoffmann, Peter Holmans, Peter A. Fischer, Peter Riederer, Qiong Yang, Rachel Marshall, Rajesh N. Kalaria, Richard Mayeux, Rik Vandenberghe, Roberta Cecchetti, Roberta Ghidoni, Ruth Frikke-Schmidt, Sandro Sorbi, Sara Haegg, Sebastiaan Engelborghs, Seppo Helisalmi, Sigrid Botne Sando, Silke Kern, Silvana Archetti, Silvia Boschi, Silvia Fostinelli, Silvia Gil, Silvia Mendoza, Simon Mead, Simona Ciccone, Srdjan Djurovic, Stefanie Heilmann-Heimbach, Steffi Riedel-Heller, Teemu Kuulasmaa, Teodoro del Ser, Thibaud Lebouvier, Thomas Polak, Tiia Ngandu, Timo Grimmer, Valentina Bessi, Valentina Escott-Price, Vilmantas Giedraitis, Vincent Deramecourt, Wolfgang Maier, Xueqiu Jian, Yolande A. L. Pijnenburg, Patrick Gavin Kehoe, Guillermo Garcia-Ribas, Pascual Sanchez-Juan, Pau Pastor, Jordi Perez-Tur, Gerard Pinol-Ripoll, Adolfo Lopez De Munain, Jose Maria Garcia-Alberca, Maria J. Bullido, Victoria Alvarez, Alberto Lleo, Luis M. Real, Pablo Mir Miguel Medina, Philip Scheltens, Henne Holstege, Marta Marquie, Maria Eugenia Saez, Angel Carracedo, Philippe Amouyel, Gerard D. Schellenberg, Julie Williams, Sudha Seshadri, CorneliaM. Van Duijn, Karen A. Mather, Raquel Sanchez-Valle, Manuel Serrano-Rios, Adelina Orellana, Lluis Tarraga, Kaj Blennow, Ole A. Andreassen, Danielle Posthuma, Jordi Clarimon, Merce Boada, Wiesje M. Van der Flier, Alfredo Ramirez, Jean-Charles Lambert, Sven J. Van der Lee, Agustin Ruiz

NATURE COMMUNICATIONS (2023)

Article Immunology

ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

Judith S. Currier, Carlee Moser, Joseph J. Eron, Kara W. Chew, Davey M. Smith, Arzhang Cyrus Javan, David Alain Wohl, Eric S. Daar, Michael D. Hughes

Summary: The clinical trial is registered with identifier NCT04518410.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Immune Status and SARS-CoV-2 Viral Dynamics

Yijia Li, Carlee Moser, Evgenia Aga, Judith S. Currier, David A. Wohl, Eric S. Daar, Justin Ritz, Alexander L. Greninger, Scott Sieg, Urvi M. Parikh, Robert W. Coombs, Michael D. Hughes, Joseph J. Eron, Davey M. Smith, Kara W. Chew, Jonathan Z. Li

Summary: Immunocompromised individuals with moderate/severe immunosuppression have higher nasal viral load and might have higher cumulative nasal RNA levels and plasma viremia. Immunosuppression leads to greater viral shedding and altered viral decay kinetics.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19

Mark J. Giganti, Kara W. Chew, Joseph J. Eron, Jonathan Z. Li, Mauricio Pinilla, Carlee Moser, Arzhang Cyrus Javan, William A. Fischer, Paul Klekotka, David Margolis, David Alain Wohl, Robert W. Coombs, Eric S. Daar, Davey M. Smith, Judith S. Currier, Michael D. Hughes

Summary: The level of SARS-CoV-2 RNA is predictive of hospitalization/death, but the level of anterior nasal (AN) RNA may not be a reliable marker for the efficacy of monoclonal antibody (mAb) treatment in COVID-19 trials.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Variant-Specific Viral Kinetics in Acute COVID-19

Ruy M. Ribeiro, Manish C. Choudhary, Rinki Deo, Mark J. Giganti, Carlee Moser, Justin Ritz, Alexander L. Greninger, James Regan, James P. Flynn, David A. Wohl, Judith S. Currier, Joseph J. Eron, Michael D. Hughes, Davey M. Smith, Kara W. Chew, Eric S. Daar, Alan S. Perelson, Jonathan Z. Li

Summary: Understanding variant-specific differences in SARS-CoV-2 viral kinetics is important for explaining transmission efficiency and gaining insights on pathogenesis and prevention. In this study, we found that the Delta variant had the highest viral load and the shortest time to peak viral load among multiple variants. There were no significant differences in time to viral clearance across the variants, but differences were observed in the second phase of viral decay. These results indicate that while variant-specific differences exist, all variants appear to be efficiently cleared by the host after reaching peak viral load.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial

Carlee B. Moser, Kara W. Chew, Justin Ritz, Matthew Newell, Arzhang Cyrus Javan, Joseph J. Eron, Eric S. Daar, David A. Wohl, Judith S. Currier, Davey M. Smith, Michael D. Hughes

Summary: During the COVID-19 pandemic, adaptive platform trials were used to quickly assess therapeutics, such as the ACTIV-2 trial, which evaluated 7 investigational agents with different administration routes. The trial compared safety and efficacy outcomes of each agent to a pooled placebo control group. The implementation of a pooled placebo design resulted in a 6% reduction in sample size compared to a trial with separate placebo control groups, and a 26% reduction during the phase 2 evaluation of multiple agents. This study discusses the complexities and provides insights for the design of future platform trials.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial

Kara W. Chew, Carlee Moser, Eunice Yeh, David A. Wohl, Eric S. Daar, Justin Ritz, Arzhang Cyrus Javan, Joseph J. Eron, Judith S. Currier, Davey M. Smith, Michael D. Hughes, ACTIV-A Study Team

Summary: This study evaluated the time to symptom resolution in COVID-19 patients and found that sustained resolution of targeted symptoms for 2 days was consistent with overall symptom improvement and return to health. Requiring >2 days of symptom resolution reduced the frequency of recurrences for both high-risk and standard-risk patients.

JOURNAL OF INFECTIOUS DISEASES (2023)

暂无数据